IC
LPCN icon

Ikarian Capital’s Lipocine LPCN Stock Holding History

Ikarian Capital’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.06M Buy
508,556
+309,014
+155% +$2.69M 0.33% 69
2025
Q4 		$1.6M Buy
+199,542
New +$671K 0.13% 113

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital's LPCN Position: Q1 2026 in Review

Ikarian Capital increased its Lipocine (LPCN) stake by 155% in Q1 2026, buying an estimated $2.69M and bringing the position to 508,556 shares worth $4.06M. The position accounts for 0.33% of the portfolio, ranked #69.

Ikarian Capital first reported a position in LPCN in Q4 2025 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Ikarian Capital held 508,556 shares of Lipocine worth $4.06M as of Q1 2026.
  • Ikarian Capital bought 309,014 Lipocine shares in Q1 2026, an estimated $2.69M.
  • Lipocine made up 0.33% of Ikarian Capital's portfolio in Q1 2026, its #69 holding.
  • Ikarian Capital first reported a position in Lipocine in Q4 2025 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.